2007 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN)

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1398-1402

  Colbert, Robert A ^a   Deodhar, Atul A ^b   Khan, Muhammad Asim ^c   Lories, Rik J ^d   Maksymowych, Walter P ^e   Reveille, John D ^f   Ritchlin, Christopher T ^g   Rosenbaum, James T ^b   Targan, Stephan R ^h   Weisman, Michael ^h   Clegg, Daniel O ⁱ  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 17; INTERLEUKIN 23; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; BONE MARROW EDEMA; CONFERENCE PAPER; EDEMA; EDUCATION; ENTERITIS; HUMAN; INFLAMMATION; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RESEARCH; RHEUMATOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLITIS;

ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; SPONDYLITIS, ANKYLOSING;

EID: 47349096817     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (53)

1. Ward MM, Bruckel J, Colbert R, et al. Summary of the 2005 Annual Research and Education Meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2005;33:978-82.
2. Khan MA, Clegg DO, Deodhar AA, et al. 2006 annual research and education meeting of the Spondyloarthritis Research and Therapy Network (SPARTAN). J Rheumatol 2007;34:1118-24.
3. Khan MA. Update on spondyloarthropathies. Ann Intern Med 2002;136:896-907.
4. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25.
5. Brown MA, Kennedy LG, MacGregor AJ, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997;40:1823-8.
6. Reveille JD. Major histocompatibility genes and ankylosing spondylitis. Best Pract Res Clin Rheumatol 2006;20:601-9.
7. Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996;55:66-8.
8. Tsui FW, Tsui HW, Cheng EY, et al. Novel genetic markers in the 5′-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis Rheum 2003;48:791-7.
9. Burton PR, Clayton DG, Cardon LR, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
10. Weber U, Pfirrmann CW, Kissling RO, Hodler J, Zanetti M. Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord 2007;8:20.
11. Walsh MC, Kim N, Kadono Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006;24:33-63.
12. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31.
13. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B, et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum 2007;56:1118-24.
14. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2845-51.
15. Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006;54:1805-13.
16. Yin T, Li L. The stem cell niches in bone. J Clin Invest 2006;116:1195-201.
17. Goldring SR, Goldring MB. Eating bone or adding it: the Wnt pathway decides. Nat Med 2007;13:133-4.
18. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-33.
19. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
20. van der Heijde DMFM, Wanders A, Mielants H, Dougados M, Landewe RBM. Prediction of progression of radiographic damage over 4 years in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2004;63:OP132.
21. Maksymowych WP, Landewe R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 2007;56:1846-53.
22. Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 2004;51:691-9.
23. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 2004;50:2942-53.
24. Marhoffer W, Stracke H, Masoud I, et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
25. Franck H, Meurer T, Hofbauer LC. Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 2004;31:2236-41.
26. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-65.
27. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. J Rheumatol 2005;32:1911-7.
28. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007;34:1753-9.
29. Maksymowych WP, Patra K, Inman RD, Rahman P, Wong R. Adalimumab suppresses biomarkers of cartilage degradation in active ankylosing spondylitis - results of the Canada AS study [abstract]. Arthritis Rheum 2005;52 Suppl:L6.
30. Wendling D, Cedoz JP, Racadot E, Dumoulin G. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 2007;74:304-5.
31. Dangoria NS, DeLay ML, Kingsbury DJ, et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002;277:23459-68.
32. Mear JP, Schreiber KL, Munz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999;163:6665-70.
33. Turner MJ, Sowders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. J Immunol 2005;175:2438-48.
34. Turner MJ, Delay ML, Bai S, Klenk E, Colbert RA. HLA-B27 upregulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: Implications for the pathogenesis of spondylarthritis-like disease. Arthritis Rheum 2007;56:215-23.
35. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007;34:2285-90.
36. Gu J, Rihl M, Marker-Hermann E, et al. Clues to pathogenesis of spondyloarthropathy derived from synovial fluid mononuclear cell gene expression profiles. J Rheumatol 2002;29:2159-64.
37. Luyten FP, Lories RJ, Verschueren P, de Vlam K, Westhovens R. Contemporary concepts of inflammation, damage and repair in rheumatic diseases. Best Pract Res Clin Rheumatol 2006;20:829-48.
38. Lories RJ, Luyten FP. Bone morphogenetic proteins in destructive and remodeling arthritis. Arthritis Res Ther 2007;9:207.
39. Matthys P, Lories RJ, De Klerck B, Heremans H, Luyten FP, Billiau A. Dependence on interferon-gamma for the spontaneous occurrence of arthritis in DBA/1 mice. Arthritis Rheum 2003;48:2983-8.
40. Lories RJ, Matthys P, de Vlam K, Derese I, Luyten FP. Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis. Ann Rheum Dis 2004;63:595-8.
41. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
42. Lories RJ, Daans M, Derese I, et al. Noggin haploinsufficiency differentially affects tissue responses in destructive and remodeling arthritis. Arthritis Rheum 2006;54:1736-46.
43. Lories RJ. Animal models of spondyloarthritis. Curr Opin Rheumatol 2006;18:342-6.
44. Lories RJ, Derese I, de Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
45. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
46. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006;116:1310-6.
47. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl:5-36.
48. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004;126:414-24.
49. Devlin SM, Yang H, Ippoliti A, et al. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 2007;132:576-86.
50. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut 2005;54:1232-6.
51. Papadakis KA, Yang H, Ippoliti A, et al. Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis 2007;13:524-30.
52. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-506.
53. Prehn JL, Thomas LS, Landers CJ, Yu QT, Michelsen KS, Targan SR. The T cell costimulator TL1A is induced by Fc-gamma-R signaling in human monocytes and dendritic cells. J Immunol 2007;178:4033-8.